We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Biovail Abandons Wellbutrin Litigation

Law360 (March 5, 2007, 12:00 AM EST) -- After years of warring over Wellbutrin, Canadian pharmaceutical company Biovail Corp. has thrown in the towel and agreed to a “comprehensive” settlement with a slew of drugmakers seeking to launch a generic version of the blockbuster antidepressant.

On Monday, Biovail revealed that it had reached an agreement with Anchen Pharmaceuticals LLP, Impax Laboratories Inc., Watson Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. in its long-standing battle over Wellbutrin XL.

Biovail had begun legal proceedings against the companies in 2005 after they filed abbreviated new drug applications...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.